' Akciju kurss '

Datums	Hansoh Pharmaceutical Group Company Apgrozījums	Hansoh Pharmaceutical Group Company EBIT	Hansoh Pharmaceutical Group Company Peļņa
2029e	17,61 miljardi undefined	0 undefined	0 undefined
2028e	16,25 miljardi undefined	5,61 miljardi undefined	0 undefined
2027e	14,91 miljardi undefined	5,25 miljardi undefined	0 undefined
2026e	14,00 miljardi undefined	4,36 miljardi undefined	4,27 miljardi undefined
2025e	12,61 miljardi undefined	3,85 miljardi undefined	3,77 miljardi undefined
2024e	12,13 miljardi undefined	3,86 miljardi undefined	3,80 miljardi undefined
2023	10,10 miljardi undefined	2,65 miljardi undefined	3,28 miljardi undefined
2022	9,38 miljardi undefined	2,57 miljardi undefined	2,58 miljardi undefined
2021	9,94 miljardi undefined	2,96 miljardi undefined	2,71 miljardi undefined
2020	8,69 miljardi undefined	2,78 miljardi undefined	2,57 miljardi undefined
2019	8,68 miljardi undefined	2,80 miljardi undefined	2,56 miljardi undefined
2018	7,72 miljardi undefined	2,26 miljardi undefined	1,90 miljardi undefined
2017	6,19 miljardi undefined	1,91 miljardi undefined	1,60 miljardi undefined
2016	5,43 miljardi undefined	1,79 miljardi undefined	1,48 miljardi undefined

	Apgrozījums	EBIT	Peļņa
2016	5,43 miljardi CNY	1,79 miljardi CNY	1,48 miljardi CNY
2017	6,19 miljardi CNY	1,91 miljardi CNY	1,60 miljardi CNY
2018	7,72 miljardi CNY	2,26 miljardi CNY	1,90 miljardi CNY
2019	8,68 miljardi CNY	2,80 miljardi CNY	2,56 miljardi CNY
2020	8,69 miljardi CNY	2,78 miljardi CNY	2,57 miljardi CNY
2021	9,94 miljardi CNY	2,96 miljardi CNY	2,71 miljardi CNY
2022	9,38 miljardi CNY	2,57 miljardi CNY	2,58 miljardi CNY
2023	10,10 miljardi CNY	2,65 miljardi CNY	3,28 miljardi CNY
2024e	12,13 miljardi CNY	3,86 miljardi CNY	3,80 miljardi CNY
2025e	12,61 miljardi CNY	3,85 miljardi CNY	3,77 miljardi CNY
2026e	14,00 miljardi CNY	4,36 miljardi CNY	4,27 miljardi CNY
2027e	14,91 miljardi CNY	5,25 miljardi CNY	0 CNY
2028e	16,25 miljardi CNY	5,61 miljardi CNY	0 CNY
2029e	17,61 miljardi CNY	0 CNY	0 CNY

2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
5,43	6,19	7,72	8,68	8,69	9,94	9,38	10,10	12,13	12,61	14,00	14,91	16,25	17,61
-	13,86	24,85	12,43	0,09	14,33	-5,57	7,68	20,08	3,93	11,02	6,54	8,98	8,38
92,69	92,64	92,19	91,60	90,75	91,23	90,73	89,79	-	-	-	-	-	-
5,04	5,73	7,12	7,95	7,89	9,06	8,51	9,07	0	0	0	0	0	0
1,79	1,91	2,26	2,80	2,78	2,96	2,57	2,65	3,86	3,85	4,36	5,25	5,61	0
32,90	30,95	29,20	32,22	32,03	29,78	27,34	26,19	31,80	30,50	31,11	35,17	34,49	-
1,48	1,60	1,90	2,56	2,57	2,71	2,58	3,28	3,80	3,77	4,27	0	0	0
-	8,06	19,31	34,31	0,47	5,61	-4,76	26,87	15,90	-0,84	13,41	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-
5,16	5,16	5,16	5,48	5,88	6,00	5,93	6,02	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-

2016	2017	2018	2019	2020	2021	2022
1,80	1,93	2,31	3,00	3,10	3,30	2,95
119,00	135,00	156,00	201,00	233,00	278,00	344,00
0	0	0	0	0	0	0
-669,00	-644,00	-350,00	291,00	-806,00	-747,00	-629,00
-6,00	-21,00	-43,00	-163,00	-134,00	-253,00	77,00
3,00	0	0	0	0	0	0
311,00	231,00	306,00	541,00	590,00	319,00	324,00
1,25	1,40	2,07	3,33	2,39	2,58	2,74
-238,00	-256,00	-381,00	-592,00	-1427,00	-460,00	-272,00
829,00	-614,00	-1388,00	-7075,00	-2874,00	-2259,00	-5935,00
1,07	-0,36	-1,01	-6,48	-1,45	-1,80	-5,66
0	0	0	0	0	0	0
-0,05	0	0	-0,04	-0,01	3,84	-0,04
1,30	0	0	9,53	3,17	-0,04	-0,06
-2,05	-0,73	0	7,99	-1,04	3,42	-0,82
-3301,00	-730,00	-	-	-	-	-
0	0	0	-1500,00	-4200,00	-380,00	-712,00
0,05	0,06	0,70	4,38	-2,28	3,66	-4,05
1007,58	1145,91	1690,85	2737,21	962,83	2117,03	2468,38
0	0	0	0	0	0	0

Hansoh Pharmaceutical Group Company Brutomarža	Hansoh Pharmaceutical Group Company Peļņas marge	Hansoh Pharmaceutical Group Company EBIT marža	Hansoh Pharmaceutical Group Company Peļņas marge
2029e	89,78 %	0 %	0 %
2028e	89,78 %	34,49 %	0 %
2027e	89,78 %	35,17 %	0 %
2026e	89,78 %	31,11 %	30,52 %
2025e	89,78 %	30,50 %	29,88 %
2024e	89,78 %	31,80 %	31,31 %
2023	89,78 %	26,19 %	32,44 %
2022	90,73 %	27,34 %	27,54 %
2021	91,24 %	29,79 %	27,31 %
2020	90,76 %	32,03 %	29,56 %
2019	91,60 %	32,22 %	29,45 %
2018	92,19 %	29,21 %	24,64 %
2017	92,64 %	30,95 %	25,79 %
2016	92,69 %	32,89 %	27,17 %

	Brutomarža	EBIT marža	Peļņas marge
2016	92,69 %	32,89 %	27,17 %
2017	92,64 %	30,95 %	25,79 %
2018	92,19 %	29,21 %	24,64 %
2019	91,60 %	32,22 %	29,45 %
2020	90,76 %	32,03 %	29,56 %
2021	91,24 %	29,79 %	27,31 %
2022	90,73 %	27,34 %	27,54 %
2023	89,78 %	26,19 %	32,44 %
2024e	89,78 %	31,80 %	31,31 %
2025e	89,78 %	30,50 %	29,88 %
2026e	89,78 %	31,11 %	30,52 %
2027e	89,78 %	35,17 %	0 %
2028e	89,78 %	34,49 %	0 %
2029e	89,78 %	0 %	0 %

Datums	Hansoh Pharmaceutical Group Company Apgrozījums uz vienu akciju	Hansoh Pharmaceutical Group Company EBIT uz vienu akciju	Hansoh Pharmaceutical Group Company Peļņa uz vienu akciju
2029e	2,97 undefined	0 undefined	0 undefined
2028e	2,74 undefined	0 undefined	0 undefined
2027e	2,52 undefined	0 undefined	0 undefined
2026e	2,36 undefined	0 undefined	0,72 undefined
2025e	2,13 undefined	0 undefined	0,64 undefined
2024e	2,05 undefined	0 undefined	0,64 undefined
2023	1,68 undefined	0,44 undefined	0,54 undefined
2022	1,58 undefined	0,43 undefined	0,44 undefined
2021	1,66 undefined	0,49 undefined	0,45 undefined
2020	1,48 undefined	0,47 undefined	0,44 undefined
2019	1,59 undefined	0,51 undefined	0,47 undefined
2018	1,50 undefined	0,44 undefined	0,37 undefined
2017	1,20 undefined	0,37 undefined	0,31 undefined
2016	1,05 undefined	0,35 undefined	0,29 undefined

	Apgrozījums uz vienu akciju	EBIT uz vienu akciju	Peļņa uz vienu akciju
2016	1,05 CNY	0,35 CNY	0,29 CNY
2017	1,20 CNY	0,37 CNY	0,31 CNY
2018	1,50 CNY	0,44 CNY	0,37 CNY
2019	1,59 CNY	0,51 CNY	0,47 CNY
2020	1,48 CNY	0,47 CNY	0,44 CNY
2021	1,66 CNY	0,49 CNY	0,45 CNY
2022	1,58 CNY	0,43 CNY	0,44 CNY
2023	1,68 CNY	0,44 CNY	0,54 CNY
2024e	2,05 CNY	0 CNY	0,64 CNY
2025e	2,13 CNY	0 CNY	0,64 CNY
2026e	2,36 CNY	0 CNY	0,72 CNY
2027e	2,52 CNY	0 CNY	0 CNY
2028e	2,74 CNY	0 CNY	0 CNY
2029e	2,97 CNY	0 CNY	0 CNY

	Akciju skaits
2016	5,16 miljardi Aktien
2017	5,16 miljardi Aktien
2018	5,16 miljardi Aktien
2019	5,48 miljardi Aktien
2020	5,88 miljardi Aktien
2021	6,00 miljardi Aktien
2022	5,93 miljardi Aktien
2023	6,02 miljardi Aktien
2024e	6,02 miljardi Aktien
2025e	6,02 miljardi Aktien
2026e	6,02 miljardi Aktien
2027e	6,02 miljardi Aktien
2028e	6,02 miljardi Aktien
2029e	6,02 miljardi Aktien

Datums	Hansoh Pharmaceutical Group Company Dividende
2029e	0,20 undefined
2028e	0,20 undefined
2027e	0,20 undefined
2026e	0,21 undefined
2025e	0,20 undefined
2024e	0,21 undefined
2023	0,19 undefined
2022	0,23 undefined
2021	0,08 undefined

	Dividende	Dividende (prognoze)
2016	0 CNY	0 CNY
2017	0 CNY	0 CNY
2018	0 CNY	0 CNY
2019	0 CNY	0 CNY
2020	0 CNY	0 CNY
2021	0,08 CNY	0 CNY
2022	0,23 CNY	0 CNY
2023	0,19 CNY	0 CNY
2024e	0 CNY	0,21 CNY
2025e	0 CNY	0,20 CNY
2026e	0 CNY	0,21 CNY
2027e	0 CNY	0,20 CNY
2028e	0 CNY	0,20 CNY
2029e	0 CNY	0,20 CNY

Datums	Hansoh Pharmaceutical Group Company Izplatīšanas likme
2029e	37,80 %
2028e	38,60 %
2027e	37,72 %
2026e	37,07 %
2025e	41,00 %
2024e	35,10 %
2023	35,10 %
2022	52,78 %
2021	17,43 %
2020	35,10 %
2019	35,10 %
2018	35,10 %
2017	35,10 %
2016	35,10 %

	Izplatīšanas likme
2016	35,10 %
2017	35,10 %
2018	35,10 %
2019	35,10 %
2020	35,10 %
2021	17,43 %
2022	52,78 %
2023	35,10 %
2024e	35,10 %
2025e	41,00 %
2026e	37,07 %
2027e	37,72 %
2028e	38,60 %
2029e	37,80 %

%	Nosaukums	Akcijas	Izmaiņas	Datums
65,81 %	Zhong (Huijuan)	3 900 000 000	0	29.04.2023.
16,03 %	Cen (Junda)	950 000 000	0	1.09.2023.
1,92 %	Fidelity Management & Research Company LLC	113 965 695	11 777 867	29.02.2024.
0,53 %	The Vanguard Group, Inc.	31 343 444	-360 000	31.03.2024.
0,50 %	FIL Investment Management (Hong Kong) Limited	29 735 359	-1 757 555	29.02.2024.
0,46 %	UBS Asset Management (Hong Kong) Limited	27 523 481	-22 000	31.12.2023.
0,41 %	BlackRock Institutional Trust Company, N.A.	24 052 609	-250 000	31.03.2024.
0,35 %	Federated Hermes International	20 700 249	243 568	31.12.2023.
0,34 %	FIL Investment Management (Singapore) Ltd.	20 295 197	-2 810 023	29.02.2024.
0,32 %	Bosera Asset Management Co., Ltd.	19 032 000	4 672 000	31.12.2023.
0,30 %	Hang Seng Investment Management Ltd.	17 848 002	-239 454	31.03.2024.
0,28 %	Fidelity International	16 361 328	-867 816	29.02.2024.
0,26 %	BlackRock Advisors (UK) Limited	15 344 000	446 000	31.03.2024.
0,24 %	GF Fund Management Co., Ltd.	14 358 000	8 792 000	31.12.2023.
0,23 %	State Street Global Advisors Asia Ltd.	13 365 578	52 380	31.10.2023.
0,22 %	APG Asset Management N.V.	13 197 027	12 046 080	30.09.2023.
0,19 %	ZhongGeng Fund Management Co., Ltd.	11 328 000	6 758 000	30.06.2023.
0,18 %	Norges Bank Investment Management (NBIM)	10 786 186	-3 033 404	31.12.2023.
0,15 %	China Asset Management Co., Ltd.	8 700 000	3 414 156	31.12.2023.
0,11 %	E Fund Management Co. Ltd.	6 348 000	4 970 000	31.12.2023.
0,09 %	Geode Capital Management, L.L.C.	5 530 000	298 000	29.02.2024.
0,08 %	HuaAn Fund Management Co., Ltd.	4 834 000	4 812 000	31.12.2023.
0,08 %	Dimensional Fund Advisors, L.P.	4 750 000	0	31.03.2024.
0,08 %	Pictet Asset Management Ltd.	4 480 000	-86 000	31.12.2023.
0,06 %	Amundi Asset Management, SAS	3 766 000	160 000	31.03.2024.
0,06 %	Northern Trust Global Investments Limited	3 419 084	0	29.02.2024.
0,06 %	UBS Asset Management (UK) Ltd.	3 324 970	-84 000	31.03.2024.
0,05 %	Royal London Asset Management Ltd.	3 208 000	0	31.12.2023.
0,05 %	JPMorgan Asset Management (Asia Pacific) Limited	3 072 000	354 000	29.02.2024.
0,05 %	Royal London Asset Management (CIS) Limited_NLE	2 782 000	0	31.08.2023.
0,04 %	CPP Investment Board	2 593 000	2 593 000	31.03.2023.
0,04 %	INVESCO Asset Management Limited	2 564 000	-4000	31.12.2023.
0,04 %	Essence Fund Management Co., Ltd.	2 454 000	2 444 000	31.12.2023.
0,04 %	Aviva Investors Global Services Limited	2 089 778	-212 884	29.02.2024.
0,03 %	Credit Suisse Funds AG	2 064 000	54 000	31.03.2024.
0,03 %	China Universal Asset Management Co., Ltd.	1 868 000	678 000	31.12.2023.
0,03 %	Nuveen LLC	1 803 582	1162	31.03.2024.
0,03 %	Amundi Japan Ltd.	1 750 000	-24 000	31.03.2024.
0,03 %	BlackRock (Singapore) Limited	1 721 321	427 474	31.03.2024.
0,03 %	China Asset Management (Hong Kong) Limited	1 578 505	-83 236	31.03.2024.
0,03 %	State Street Global Advisors (US)	1 554 087	-50 000	31.03.2024.
0,03 %	DWS Investment GmbH	1 540 144	37 391	31.03.2024.
0,03 %	CSOP Asset Management Limited	1 488 729	31 703	31.03.2024.
0,03 %	Harvest Fund Management Co., Ltd.	1 486 000	252 000	31.12.2023.
0,02 %	State Street Global Advisors (UK) Ltd.	1 437 980	2	31.03.2024.
0,02 %	DWS Investments UK Limited	1 437 610	23 085	31.03.2024.
0,02 %	Charles Schwab Investment Management, Inc.	1 267 724	0	31.03.2024.
0,02 %	Penghua Fund Management Co., Ltd.	1 262 000	200 000	31.12.2023.
0,02 %	Mirae Asset Global Investments (Hong Kong) Limited	1 122 286	241 242	31.03.2024.
0,02 %	HSBC Global Asset Management (UK) Limited	1 081 556	-57 563	29.02.2024.
0,02 %	Storebrand Kapitalforvaltning AS	1 054 602	26 000	29.02.2024.
0,02 %	BlackRock Investment Management (UK) Ltd.	1 052 000	-74 000	29.02.2024.
0,02 %	Handelsbanken Kapitalförvaltning AB	1 008 000	72 000	31.03.2024.
0,02 %	Fullgoal Fund Management Co., Ltd.	972 000	742 000	31.12.2023.
0,02 %	Lyu (Aifeng)	955 500	90 000	15.06.2023.
0,02 %	KLP Fondsforvaltning AS	934 000	0	29.02.2024.
0,02 %	GAM International Management Ltd.	900 000	0	29.02.2024.
0,01 %	UBS Asset Management (Switzerland)	888 000	0	29.02.2024.
0,01 %	Irish Life Investment Managers Ltd.	860 900	-3100	31.03.2024.
0,01 %	PGGM Vermogensbeheer B.V.	859 328	3043	31.07.2023.
0,01 %	Bank of China Investment Management Co., Ltd.	856 000	620 000	30.06.2023.
0,01 %	Goldman Sachs Advisors B.V._NLE	822 000	56 000	30.11.2023.
0,01 %	Zürcher Kantonalbank (Asset Management)	780 480	220 000	29.02.2024.
0,01 %	Mercer Global Investments Management Ltd	777 809	0	31.03.2024.
0,01 %	China Southern Asset Management Co. Ltd.	760 000	228 000	31.12.2023.
0,01 %	American Century Investment Management, Inc.	750 000	128 000	31.03.2024.
0,01 %	Mellon Investments Corporation	738 100	122 000	31.03.2024.
0,01 %	Dimensional Fund Advisors, Ltd.	704 000	0	29.02.2024.
0,01 %	Lazard Asset Management, L.L.C.	696 000	0	31.12.2023.
0,01 %	Baoying Fund Management Co., Ltd.	622 719	622 719	31.12.2023.
0,01 %	BOCI-Prudential Asset Management Ltd.	586 744	0	29.02.2024.
0,01 %	Robeco Institutional Asset Management B.V.	544 000	390 000	29.02.2024.
0,01 %	Legal & General Investment Management Ltd.	540 000	-64 000	29.02.2024.
0,01 %	Northern Trust Investments, Inc.	530 000	-8000	31.03.2024.
0,01 %	Tianhong Asset Management Co., Ltd.	526 000	234 000	31.12.2023.
0,01 %	Yinhua Fund Management Co., Ltd.	482 000	302 000	31.12.2023.
0,01 %	British Columbia Investment Management Corp.	481 158	-15 539	31.03.2023.
0,01 %	Cardano Asset Management NV	475 137	55	29.02.2024.
0,01 %	GAM (Luxembourg) S.A.	450 000	-100 000	29.02.2024.
0,01 %	California State Teachers Retirement System	442 000	-90 000	30.06.2023.
0,01 %	Swedbank Robur Fonder AB	424 000	-22 000	29.02.2024.
0,01 %	BMO Asset Management Inc.	419 440	0	31.03.2024.
0,01 %	Sun (Yuan)	408 100	408 100	29.04.2023.
0,01 %	Maxwealth Fund Management Co., Ltd.	400 000	400 000	30.06.2023.
0,01 %	Bellevue Asset Management AG	400 000	100 000	29.02.2024.
0,01 %	Eurizon Capital S.A.	386 393	6254	29.02.2024.
0,01 %	Hony Horizon Fund Management Co., Ltd.	386 000	386 000	31.12.2023.
0,01 %	Mirae Asset Global Investments (USA) LLC	347 943	6000	31.03.2024.
0,01 %	Hwabao WP Fund Management Co., Ltd.	340 000	154 000	31.12.2023.
0,01 %	Morgan Stanley Investment Management (China) Company Limited.	338 000	338 000	31.12.2023.
0,01 %	Krane Funds Advisors, LLC	336 000	0	31.03.2024.
0,01 %	UBS Asset Management Switzerland AG	334 000	0	29.02.2024.
0,01 %	Nykredit Bank AS	326 000	86 000	29.02.2024.
0,01 %	Vestcor Inc	314 081	-158 824	31.12.2022.
0,01 %	Guliver Anlageberatung GmbH	306 000	64 000	31.01.2024.
0,00 %	Vanguard Investments Australia Ltd.	295 611	151	29.02.2024.
0,00 %	OP Varainhoito Oy	286 000	0	29.02.2024.
0,00 %	Huatai-PineBridge Fund Management Co., Ltd.	268 630	20 000	31.12.2023.
0,00 %	Degroof Petercam Asset Management	262 269	0	31.12.2023.
0,00 %	Oberweis Asset Management, Inc.	250 000	250 000	31.12.2023.

What values and corporate philosophy does Hansoh Pharmaceutical Group Company represent?

Hansoh Pharmaceutical Group Co Ltd represents values of innovation, quality, and patient-centricity. With a strong corporate philosophy, the company focuses on developing and delivering high-quality pharmaceutical products that improve and save lives. Hansoh Pharmaceutical Group Co Ltd's commitment to innovation drives the development of new and effective therapies to address unmet medical needs. The company's patient-centric approach ensures that their products are developed and manufactured with the highest quality standards, aiming to provide optimal healthcare solutions for patients worldwide. Hansoh Pharmaceutical Group Co Ltd's dedication to excellence makes them a trusted and reliable player in the pharmaceutical industry.

In which countries and regions is Hansoh Pharmaceutical Group Company primarily present?

Hansoh Pharmaceutical Group Co Ltd is primarily present in China.

What significant milestones has the company Hansoh Pharmaceutical Group Company achieved?

Hansoh Pharmaceutical Group Co Ltd has achieved several significant milestones. In recent years, the company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a major milestone in its financial development. Additionally, Hansoh Pharmaceutical Group has made significant advancements in its research and development efforts, resulting in the successful launch of innovative and high-quality pharmaceutical products. The company has also expanded its global footprint by establishing strategic collaborations and partnerships with international pharmaceutical companies. Overall, Hansoh Pharmaceutical Group Co Ltd continues to make notable strides in the pharmaceutical industry, solidifying its position as a leading player in the market.

What is the history and background of the company Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Co Ltd is a leading pharmaceutical company with a rich history and background. Founded in 1995, the company has rapidly grown to become one of the largest and most respected pharmaceutical companies in China. Hansoh Pharmaceutical focuses on the research, development, manufacturing, and commercialization of innovative drugs in various therapeutic areas like oncology, diabetes, and cardiovascular diseases. With a strong emphasis on innovation and quality, Hansoh Pharmaceutical has successfully introduced numerous blockbuster drugs, gaining recognition both domestically and internationally. The company's commitment to excellence and patient care has established it as a trusted name in the pharmaceutical industry.

Who are the main competitors of Hansoh Pharmaceutical Group Company in the market?

The main competitors of Hansoh Pharmaceutical Group Co Ltd in the market include well-known pharmaceutical companies such as Shanghai Pharmaceuticals Holding Co Ltd, Jiangsu Hengrui Medicine Co Ltd, and Sino Biopharmaceutical Ltd. These companies compete with Hansoh Pharmaceutical Group Co Ltd in terms of research and development, product portfolio, market presence, and overall performance in the pharmaceutical industry.

In which industries is Hansoh Pharmaceutical Group Company primarily active?

Hansoh Pharmaceutical Group Co Ltd primarily operates in the pharmaceutical industry.

What is the business model of Hansoh Pharmaceutical Group Company?

The business model of Hansoh Pharmaceutical Group Co Ltd is focused on research, development, manufacturing, and commercialization of innovative pharmaceutical products. As one of the leading pharmaceutical companies in China, Hansoh Pharmaceutical Group Co Ltd aims to provide high-quality and affordable medications to improve the well-being of individuals. The company collaborates with healthcare professionals and institutions to meet the evolving healthcare needs of patients. Hansoh Pharmaceutical Group Co Ltd's business model emphasizes continuous innovation, leveraging cutting-edge technology, and maintaining strong partnerships across the industry. Through its diversified portfolio and commitment to excellence, the company strives to contribute to the advancement of healthcare in China and globally.

Kāds ir Hansoh Pharmaceutical Group Company 2024 KGV?

Hansoh Pharmaceutical Group Company KGV ir 25,04.

Kāds ir Hansoh Pharmaceutical Group Company 2024 KUV?

Hansoh Pharmaceutical Group Company KUV ir 7,84.

Kāds AlleAktien kvalitātes vērtējums ir Hansoh Pharmaceutical Group Company?

AlleAktien kvalitātes vērtējums Hansoh Pharmaceutical Group Company ir 3/10.

Cik liels ir Hansoh Pharmaceutical Group Company 2024 apgrozījums?

gaidāmā Hansoh Pharmaceutical Group Company apgrozījums ir 12,13 miljardi CNY.

Cik liels ir Hansoh Pharmaceutical Group Company 2024 peļņa?

gaidāmā Hansoh Pharmaceutical Group Company peļņa ir 3,80 miljardi CNY.

Kas ir Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Co Ltd is a leading Chinese pharmaceutical company specializing in research, development, production, and distribution of innovative and generic drugs. The company originated in Jiangsu province, China and operates globally today. The business model of Hansoh consists of various divisions focusing on drug development, manufacturing, distribution, and marketing. The company has a strong presence in the Asian market and is expanding its business worldwide. The divisions of Hansoh include research and development of new drugs, generics, over-the-counter products, and biological drugs. The company is renowned for its capabilities in active ingredient research, development, and manufacturing. Hansoh's products cover a wide range of therapeutic areas including oncology, cardiology, neurology, and infectious diseases. In the research and development field, Hansoh drives growth through investments in cutting-edge technologies like new drug research in collaboration with universities and research institutes, artificial intelligence and big data, as well as close cooperation with other companies. The generics division is a crucial part of Hansoh's business model. The company offers a wide range of generics, providing a cost-effective yet effective alternative to expensive brand-name products. The company works towards lowering production costs in the long term and facilitating access to medication for patients worldwide. Additionally, the company operates in the over-the-counter (OTC) sector, offering products such as vitamins, pain relievers, and non-prescription medications. Hansoh also focuses heavily on biological drugs, particularly in the field of antibody therapy. Here, the company works on developing new drugs for the treatment of cancer and other serious illnesses. To make Hansoh Pharma's business successful, the company has established a strong presence in key markets around the world. Collaboration with other pharmaceutical companies to jointly market and distribute their products is a crucial aspect. For example, Germany and the USA are important markets for the company. Overall, the business model of Hansoh Pharmaceutical Group Co Ltd is focused on the long-term sustainability and growth of their business. Through a combination of innovative development and production processes, a broad portfolio of drugs, and a strong presence in key markets worldwide, the company remains on a growth trajectory and will establish itself as a significant player in the global pharmaceutical industry in the future.

Cik liela ir Hansoh Pharmaceutical Group Company dividende?

Hansoh Pharmaceutical Group Company izmaksā dividendes 0,23 CNY, kas tiek izmaksātas reizes gadā.

Cik bieži Hansoh Pharmaceutical Group Company maksā dividendes?

Dividendes pašlaik nevar aprēķināt Hansoh Pharmaceutical Group Company vai uzņēmums nedod dividendes.

Kas ir Hansoh Pharmaceutical Group Company ISIN?

Hansoh Pharmaceutical Group Company ISIN ir KYG549581067.

Kas ir Hansoh Pharmaceutical Group Company WKN?

Hansoh Pharmaceutical Group Company WKN ir A2PLRC.

Kas ir Hansoh Pharmaceutical Group Company biržas kods?

Hansoh Pharmaceutical Group Company simbols ir 3692.HK.

Cik lielu dividendēm maksā Hansoh Pharmaceutical Group Company?

Pēdējo 12 mēnešu laikā Hansoh Pharmaceutical Group Company maksāja dividendes 0,19 CNY apmērā. Tas atbilst aptuveni 1,21 % dividendes ražībai. Nākamajos 12 mēnešos Hansoh Pharmaceutical Group Company plāno maksāt dividendes 0,20 CNY apmērā.

Cik augsta ir Hansoh Pharmaceutical Group Company dividendu rentabilitāte?

Hansoh Pharmaceutical Group Company pašreizējā dividendu rentabilitāte ir 1,21 %.

Kad Hansoh Pharmaceutical Group Company maksā dividendes?

Hansoh Pharmaceutical Group Company maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos oktobris, jūlijs, oktobris, jūlijs.

Cik droša ir Hansoh Pharmaceutical Group Company dividende?

Hansoh Pharmaceutical Group Company pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Cik liela ir Hansoh Pharmaceutical Group Company dividende?

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,20 CNY. Tas atbilst dividendes ražībai 1,29 %.

Kurā sektorā atrodas Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Company tiek piešķirts nozarei "Veselība".

Wann musste ich die Aktien von Hansoh Pharmaceutical Group Company kaufen, um die vorherige Dividende zu erhalten?

Lai saņemtu pēdējo dividendu Hansoh Pharmaceutical Group Company apmērā 0,142 CNY, kas tika izmaksāta 17.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 19.06.2024..

Kad Hansoh Pharmaceutical Group Company izmaksāja pēdējo dividendē?

Pēdējās dividendes izmaksa notika 17.07.2024..

Cik liela bija Hansoh Pharmaceutical Group Company dividende gadā 2023?

Gadā 2023, Hansoh Pharmaceutical Group Company izmaksāja 0,23 CNY dividendes.

Kādā valūtā Hansoh Pharmaceutical Group Company izmaksā dividendes?

Hansoh Pharmaceutical Group Company dividendes tiek izmaksātas CNY.

Tiešās emisijas	9024,6
Nepārtrauktas emisijas no iegādātās enerģijas	77 719,97
Nepārtrauktas emisijas vērtību ķēdē	—
CO₂ emisijas	86 744,57
CO₂ samazināšanas stratēģija	✅
Oglekļa enerģija	❌
Atomenerģija	❌
Dzīvnieku izmēģinājumi	❌
Pelz & Leder	—
Pesticīdi	—
Palmas eļļa	—
Tabaka	❌
Ģenētiskā inženierija	❌
Klimata koncepcija	—
Ilgspējīga mežsaimniecība	—
Atkritumu pārstrādes noteikumi	✅
Videi draudzīga iepakojuma	✅
Bīstamās vielas	✅
Degvielas patēriņš un efektivitāte	✅
Ūdens patēriņš un efektivitāte	✅

Sieviešu īpatsvars darbinieku vidū	35,769
Sieviešu īpatsvars vadībā	—
Āzijas darbinieku īpatsvars	—
Āzijas vadības daļa	—
Hispano/latīņamerikāņu darbinieku īpatsvars	—
Hispano/latīņu pārstāvniecība vadībā	—
Akciju procentuālais daudzums melnādaino darbinieku vidū	—
Daļa melnādaino vadītāju	—
Baltie darbinieku īpatsvars	—
Baltie pārvaldības procenti	—
Pieaugušo satura	❌
Alkohols	❌
Aizsardzība	—
Ieroči	❌
Azartspēles	❌
Militārie līgumi	❌
Cilvēktiesību koncepcija	✅
Datumaizsardzības koncepcija	—
Darba aizsardzība un veselības aizsargāšana	✅
Katolisks	✅

Ilgtermiņa attīstības ziņojums	✅
Akciju turētāju iesaiste	✅
Atsaukšanas politika	❌
Kartel tiesības	❌

Birža	Hansoh Pharmaceutical Group Company Akciju biržas simbols
FRANKFURTE	3KY.F
HKSE	3692.HK
MINHENE	3KY.MU

Hansoh Pharmaceutical Group Company Akciju biržas simbols	Hansoh Pharmaceutical Group Company FIGI
3692:HK	BBG00P78Y7N1
3692EUR:XS	BBG00PG9MD40
3692EUR:XH	BBG00PG9MD77
3692EUR:XF	BBG00PG9MD95
3692EUR:XE	BBG00PG9MDC1
3692EUR:XJ	BBG00PG9MDD0
3692EUR:XL	BBG00PG9MDF8
3692EUR:XG	BBG00PG9MDG7
3692EUR:XO	BBG00PG9MDH6
3692EUR:XA	BBG00PG9MDM0
3692EUR:E1	BBG00PG9MDN9
3692EUR:XT	BBG00PG9MDP7
3692EUR:XW	BBG00PG9MDQ6
3692EUR:XU	BBG00PG9MDR5
3692EUR:XV	BBG00PG9MDS4
3692EUR:XM	BBG00PG9MDT3
3692EUR:XQ	BBG00PG9MDV0
3692EUR:XX	BBG00PG9MDW9
3692EUR:XZ	BBG00PG9MDX8
3692EUR:EU	BBG00PG9MDZ6
3KY:TH	BBG00PGKL8X5
3KY:GR	BBG00PGLT3M8
3KY:GF	BBG00PGLT3N7
3KY:GS	BBG00PGLT3R3
3KY:GM	BBG00PGLT3S2
3692HKD:EP	BBG00PH03PP9
3692HKD:EZ	BBG00PH03PR7
3692HKD:XS	BBG00PH03PS6
3692HKD:XH	BBG00PH03PW1
3692HKD:XF	BBG00PH03PY9
3692HKD:XE	BBG00PH03Q04
3692HKD:XJ	BBG00PH03Q13
3692HKD:XL	BBG00PH03Q22
3692HKD:XG	BBG00PH03Q31
3692HKD:XO	BBG00PH03Q40
3692HKD:XA	BBG00PH03Q86
3692HKD:E1	BBG00PH03Q95
3692HKD:XT	BBG00PH03QB2
3692HKD:XW	BBG00PH03QC1
3692HKD:XU	BBG00PH03QD0
3692HKD:XV	BBG00PH03QF8
3692HKD:XM	BBG00PH03QG7
3692HKD:XQ	BBG00PH03QH6
3692HKD:XX	BBG00PH03QJ4
3692HKD:XZ	BBG00PH03QK2
3692HKD:EU	BBG00PH03QN9
3692:H1	BBG00Q6WB3D2
3692:H2	BBG00Q6WBGD3
3KY:GZ	BBG00W9LMHM7
3692EUR:EP	BBG00W9LR9N9
3692EUR:EZ	BBG00W9LR9Q6
HNSPF:US	BBG00Z8393Z3
HNSPF:PQ	BBG00Z8394D5
HNSPF:UV	BBG00Z8394F3
3KY:LA	BBG018H9RRP7
3KY:LU	BBG018J3F9G1

Veic labākos ieguldījumus savā dzīvē fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kurss

Akciju cena

Simbols3692.HK

ISINKYG549581067

WKNA2PLRC

Hansoh Pharmaceutical Group Company Akcijas apgrozījums, EBIT, peļņa KYG549581067 · A2PLRC

Apgrozījums, peļņa & EBIT

Apgrozījuma, EBIT un ienākumu izpratne

Gada analīze un salīdzinājumi

Ieguvumu izmantošana investīcijām

Ieguldījumu ieskati

Hansoh Pharmaceutical Group Company Apjoma, peļņas un EBIT vēsture

Hansoh Pharmaceutical Group Company Akciju Rādītāji

Peļņas un zaudējumu pārskats

Apjomi un izaugsme

Bruto marža

EBIT un EBIT marža

Ienākumi un izaugsme

Izlaistās akcijas

Gadskārtējās salīdzinājuma interpretācija

Gaidījumi un prognozes

Bilance

Bilances izpratne

Aktīvi

Parādsaistības

Pašu kapitāls

Gadu pēc gada analīze

Datu interpretācija

Hansoh Pharmaceutical Group Company akcijas maržas KYG549581067 · A2PLRC

Maržas

Brutomaržas izpratne

EBIT maržas analīze

Apjoma maržas ieskati

Gaidāmo vērtību interpretēšana

Salīdzinošā analīze

Hansoh Pharmaceutical Group Company Maržas vēsture

Hansoh Pharmaceutical Group Company akciju apgrozījums, EBIT, peļņa uz vienu akciju KYG549581067 · A2PLRC

Apjoms, EBIT un Peļņa uz vienu akciju

Apjoms uz vienu akciju

EBIT uz vienu akciju

Ienākumi uz vienu akciju

Gaidāmās vērtības

Hansoh Pharmaceutical Group Company Apjoma, peļņas un EBIT vēsture uz vienu akciju

Hansoh Pharmaceutical Group Company akcija un akciju analīze

Hansoh Pharmaceutical Group Company vērtējums pēc vēsturiskā PE, EBIT un P/S

Hansoh Pharmaceutical Group Company akciju skaits KYG549581067 · A2PLRC

Apjoms, EBIT un Peļņa uz vienu akciju

Apjoms uz vienu akciju

EBIT uz vienu akciju

Ienākumi uz vienu akciju

Gaidāmās vērtības

Hansoh Pharmaceutical Group Company Akcijas Dividende KYG549581067 · A2PLRC

Dividende

Pārskats par dividendēm

Interpretācija un pielietojums

Investīciju stratēģija

Hansoh Pharmaceutical Group Company Dividendu vēsture

Hansoh Pharmaceutical Group Company Akciju izmaksu attiecība KYG549581067 · A2PLRC

Ausschüttungsquote

Kas ir gada izmaksu kvota?

Datu interpretācija

Datu izmantošana investīcijām

Hansoh Pharmaceutical Group Company Izplatīšanas kvotu vēsture

Hansoh Pharmaceutical Group Company Peļņas prognozes

Hansoh Pharmaceutical Group Company Pelnīguma Pārsteigumi

Eulerpool ESG reitings Hansoh Pharmaceutical Group Company akcijai

Eulerpool World ESG Rating (EESG©)

82/ 100

🌱 Environment

👫 Social

🏛️ Governance

Vide (Environment)

Sociālais

Uzņēmuma vadība (Governance)

Hansoh Pharmaceutical Group Company Akciju akcionāru struktūra

Hansoh Pharmaceutical Group Company Valde un uzraudzības padome

Bieži uzdotie jautājumi par Hansoh Pharmaceutical Group Company akciju

What values and corporate philosophy does Hansoh Pharmaceutical Group Company represent?

In which countries and regions is Hansoh Pharmaceutical Group Company primarily present?

Veic labākos ieguldījumus savā dzīvē
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Simbols
3692.HK

ISIN
KYG549581067

WKN
A2PLRC